Abstract
A panel of cytolytic T lymphocyte (CTL) clones was isolated from metastases and blood samples of a melanoma patient vaccinated with MAGE-3.A1-pulsed autologous dendritic cells. We report here the identification of a new antigen encoded by the MAGE-C2 cancer-germline gene. This antigen is recognized by some of these CTL on HLA-B*4403. The sequence of the peptide is SESIKKKVL. It is processed in various melanoma cell lines expressing MAGE-C2 and HLA-B*4403. Because of the expression pattern of gene MAGE-C2, this new antigen is strictly tumor-specific and could therefore be used for peptide-based antitumoral vaccination.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Amino Acid Sequence
-
Animals
-
Antigen Presentation / immunology*
-
Antigens, Neoplasm / genetics*
-
Antigens, Neoplasm / immunology
-
COS Cells
-
Cancer Vaccines / therapeutic use
-
Chlorocebus aethiops
-
Clone Cells
-
Dendritic Cells / transplantation
-
HLA-B Antigens / immunology*
-
HLA-B44 Antigen
-
Humans
-
Melanoma / therapy
-
Molecular Sequence Data
-
Neoplasm Proteins / immunology*
-
Reverse Transcriptase Polymerase Chain Reaction
-
T-Lymphocytes, Cytotoxic / immunology*
-
Transfection
Substances
-
Antigens, Neoplasm
-
Cancer Vaccines
-
HLA-B Antigens
-
HLA-B44 Antigen
-
MAGEC2 protein, human
-
Neoplasm Proteins